# A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

> **NCT05104775** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 33 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** GNC-035

## Key facts

- **NCT ID:** NCT05104775
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-09
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05104775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05104775, "A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05104775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*